

# Propofol protects against the neurotoxicity of 1-methyl-4-phenylpyridinium

SHOUSHI WANG<sup>1</sup>, TINGTING SONG<sup>2</sup>, CUIBO LENG<sup>1</sup>, KETAO LAN<sup>3</sup>, JISHUN NING<sup>1</sup> and HAICHEN CHU<sup>4</sup>

Departments of <sup>1</sup>Anesthesiology, <sup>2</sup>Oncology and <sup>3</sup>Cardiology, Qingdao Central Hospital, Qingdao, Shandong 266042;

<sup>4</sup>Department of Anesthesiology, Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong 266003, P.R. China

Received October 28, 2014; Accepted September 22, 2015

DOI: 10.3892/mmr.2015.4570

**Abstract.** Parkinson's disease (PD) is a progressive and degenerative disorder of the central nervous system, characterized by the loss of dopaminergic neurons and muscular rigidity. Treatment with propofol (2,6-diisopropylphenol) has been observed to attenuate oxidative stress injury via inhibition of programmed cell death. Results from the present study indicate that propofol treatment attenuates 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>)-induced oxidative stress, which was demonstrated by increased levels of reactive oxygen species, 4-hydroxy-2-nonenal and protein carbonyls. Furthermore, it was demonstrated that propofol may ameliorate MPP<sup>+</sup>-induced mitochondrial dysfunction by increasing the level of ATP and the mitochondrial membrane potential. MTT and lactate dehydrogenase assays indicated that propofol treatment reduces cell vulnerability to MPP<sup>+</sup>-induced insult. Propofol was also observed to prevent apoptotic signals by reducing the ratio of Bcl-2-associated X protein to B-cell lymphoma 2, reducing the expression level of cleaved caspase-3 and attenuating cytochrome *c* release. Thus, propofol may present as a novel therapeutic strategy for the treatment of PD.

## Introduction

Parkinson's disease (PD), the second most common neurodegenerative disease in the world, is characterized by the loss of dopaminergic neurons and muscular rigidity (1). A major product of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>), which has been extensively used in a variety of *in vitro* systems to model PD (2). MPP<sup>+</sup> has been reported to be actively transported into dopaminergic neurons via the plasma membrane in

a similar manner to dopamine transporters (3). Neurotoxicity of MPTP/MPP<sup>+</sup> is complex, and the overproduction of nitric oxide (NO), hydroxyl radical generation and apoptosis have all been associated with the neurotoxicity of MPP<sup>+</sup> (4). Furthermore, MPP<sup>+</sup> was reported to induce mitochondrial dysfunction by inhibiting the activity of complex I (5). However, the intracellular mechanisms of MPP<sup>+</sup>-induced neurotoxicity underlying the degenerative process require further elucidation.

Propofol (2,6-diisopropylphenol) is an intravenous anesthetic agent that has been widely administered as a short-acting intravenous anesthetic since the late 1980s (6). In addition to its application for maintenance of sedative effects as an anesthetic, various characteristics of propofol have been investigated in recent years. Notably, propofol demonstrates anti-oxidative (7) and anti-inflammatory properties (8). Propofol is chemically similar to the endogenous antioxidant,  $\alpha$ -tocopherol (vitamin E), therefore should theoretically demonstrate similar properties (9). Increasing evidence has indicated that propofol scavenges oxygen free radicals, and inhibits oxidative damage and the release of inflammatory factors (10). Notably, a previous study demonstrated the neuroprotective effects of propofol against amyloid  $\beta$  (A $\beta$ ) toxicity in Alzheimer's disease (AD). In addition, propofol has been shown to protect the brain from ischemia-reperfusion injury (11). However, to the best of our knowledge, it is unknown whether propofol has similar protective effects on the pathophysiological changes in PD. Therefore, in the present study, the effect of propofol in reducing MPP<sup>+</sup>-induced toxicity was investigated in human SH-SY5Y cells.

## Materials and methods

**Cell culture, treatment and transfection.** SH-SY5Y human neuroblastoma cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Eagle's minimum essential medium (American Type Culture Collection) and Ham's F12 medium (American Type Culture Collection) containing 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin (100 U/ml) and streptomycin (100  $\mu$ g/ml; Lonza, Walkersville, MD, USA). Cells were exposed to 50  $\mu$ M MPP<sup>+</sup> (Sigma-Aldrich) in the presence or absence of 25 or 50  $\mu$ M propofol (Sigma-Aldrich) for 24 h.

**Correspondence to:** Dr Shoushi Wang, Department of Anesthesiology, Qingdao Central Hospital, 127 Si Liu South Road, Qingdao, Shandong 266042, P.R. China  
E-mail: wangss6806@yeah.net

**Key words:** propofol, 1-methyl-4-phenylpyridinium, oxidative stress, Parkinson's disease

**Western blot analysis.** Proteins were extracted from cultured cells using cell lysis buffer (Cell Signaling Technology, Inc., Danvers, MA, USA). Protein concentration was determined using a bicinchoninic acid protein assay kit (Sigma-Aldrich). The soluble protein solutions were mixed with 4X sample buffer (0.25 M Tris-HCl, 20% mercaptoethanol, 8% SDS, 20% sucrose, 0.008% bromophenol blue; pH 6.8) and boiled for 5 min. Equal quantities of protein (20  $\mu$ g) were loaded onto SDS-PAGE (10% separation gel and 5% spacer gel). The separation gel was then run at 80 V for 15 min and the spacer gel was run at 120 V for 1 h with 1X running buffer (25 mM Tris-HCl, 200 mM glycine, 0.1% (w/v) SDS; Bio-Rad, Hercules, CA, USA). The gel was then transferred onto a polyvinylidene fluoride membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using a transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) at 80 V for 3 h in an ice-cold environment. Following blocking in 5% skimmed milk in Tris-buffered saline with Tween-20 (TBST; 20 mM Tris-HCl, 150 mM sodium chloride, 0.1% Tween-20), the membranes were incubated with the following primary antibodies at 4°C overnight: Mouse monoclonal anti-human B cell lymphoma 2 (Bcl-2; 1:2,000; cat. no. sc-7382; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); mouse monoclonal anti-human Bcl-2-associated X protein (Bax; 1:3,000; cat. no. sc-20067; Santa Cruz Biotechnology, Inc.); mouse monoclonal anti-human cytochrome *c* (1:2,000; cat. no. sc-514435; Santa Cruz Biotechnology, Inc.); mouse monoclonal anti-human cytochrome *c* oxidase subunit IV isoform 1 (COX4; 1:5,000; cat. no. sc-376731; Santa Cruz Biotechnology, Inc.); rabbit polyclonal anti-human cleaved caspase-3 (1:1,000; cat. no. sc-22171-R; Santa Cruz Biotechnology, Inc.); mouse monoclonal anti-human  $\beta$ -actin (1:10,000; cat. no. sc-130065; Santa Cruz Biotechnology, Inc.). The membranes were subsequently incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:5,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) or HRP-conjugated goat anti-rabbit IgG (1:5,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) secondary antibodies for 1 h at room temperature. The membranes were washed three times with TBST and the proteins were detected with the enhanced chemiluminescence system (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The relative densities of protein bands were analyzed using Image J 2.1 software (National Institutes of Health, Bethesda, MA, USA).

**Protein carbonyl assay.** Cells were lysed with cell lysis buffer (Cell Signaling Technology, Inc.) and protein samples from cells were adsorbed to wells of an ELISA plate (Thermo Fisher Scientific, Inc.) and reacted with 2,4-dinitrophenylhydrazine (DNPH; Sigma-Aldrich). The hydrazone adducts were incubated with an anti-DNPH antibody (1:1,000; Sigma-Aldrich; cat. no. HPA029675) for 1 h at 37°C, and a secondary rat anti-mouse monoclonal antibody conjugated with HRP (1:3,000; Thermo Fisher Scientific, Inc.; cat. no. 04-6120) for 1 h at 37°C. The method was calibrated using oxidized bovine serum albumin (BSA; Sigma-Aldrich), and prepared as previously described (12).

**Reactive oxygen species (ROS) determination.** Fluorescent dye, 2',7'-dichlorofluorescein-diacetate (DCFH-DA;

Sigma-Aldrich) was used to measure the intracellular ROS level (13). Following the cell treatment with 50  $\mu$ M MPP<sup>+</sup> in the presence or absence of 25 or 50  $\mu$ M propofol for 24 h, SH-SY5Y cells were loaded with 10  $\mu$ M DCFH-DA and incubated in a CO<sub>2</sub> incubator for 30 min at 37°C. The cells were washed with phosphate buffered saline (PBS) three times, and fluorescence signals were recorded using a fluorescence microscope (IX71SIF-2; Olympus Corporation, Tokyo, Japan).

**4-Hydroxy-2-nonenal (4-HNE) immunofluorescence staining.** Following the indicated treatment, the cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 10 min at room temperature (RT) followed by permeabilization with 0.4% Triton X-100 (Sigma-Aldrich) on ice for 15 min. Cells were blocked with 5% BSA and 2.5% FBS in PBS with Tween-20 (Sigma-Aldrich). Subsequently, cells were incubated with anti-4-HNE (Cell Signaling Technology, Inc.) for 2 h at RT followed by incubation with Invitrogen Alexa-594-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h at RT. Staining signals were recorded using a fluorescence microscope.

**Statistical analysis.** Results are presented as the mean  $\pm$  standard error of the mean of at least three experiments. Results obtained from different experiments were analyzed using one-way analysis of variance and  $P < 0.05$  was considered to indicate a statistically significant difference.

**Cell viability determination.** An MTT (Sigma-Aldrich) reduction assay was used to determine cell viability incubated at 37°C at 5,000 per well. The cells were cultured in 96-well plates and exposed to 50  $\mu$ M MPP<sup>+</sup> in the presence or absence of 25 or 50  $\mu$ M propofol for 24 h. MTT (at a final concentration of 1.0 mg/ml) was then added to each well and incubated for 2 h at 37°C in the dark. The formed formazane crystal was dissolved in dimethyl sulfoxide (Sigma-Aldrich). The solution was agitated at room temperature for 10 min, and absorbance was determined at 570 nm using a iMark Microplate Absorbance Reader (Bio-Rad Laboratories) to index cell viability.

**Determination of lactate dehydrogenase (LDH) release.** Cells were cultured in 96-well plates and exposed to 50  $\mu$ M MPP<sup>+</sup> in the presence or absence of 25 or 50  $\mu$ M propofol for 24 h. A Cytotoxicity Detection kit (Sigma-Aldrich) was used to determine the levels of LDH released from the damaged cells, according to the manufacturer's instructions. Absorbance was determined at 490 nm using a microplate reader to quantify the levels of LDH.

**Intracellular NO determination.** The cells were exposed to 50  $\mu$ M MPP<sup>+</sup> in the presence or absence of 25 or 50  $\mu$ M propofol for 24 h. The levels of intracellular NO was then determined using a diaminofluorescein-FM diacetate (DAF-FM DA) cell-permeable fluorescent probe (Sigma-Aldrich). Briefly, 10  $\mu$ M DAF-FM DA was loaded and incubated at 37°C for 30 min in the dark. Fluorescence signals were captured using a IX71SIF-2 fluorescence microscope.

**Mitochondrial membrane potential (MMP) determination.** Cells were exposed to 50  $\mu$ M MPP<sup>+</sup> in the presence or absence




Figure 1. Protective effects of propofol against oxidative stress in SH-SY5Y cells. (A) ROS level was measured by 2',7'-dichlorofluorescein-diacetate. Representative fluorescence images of intracellular ROS and quantitative analysis demonstrated increased intracellular ROS accumulation in cells exposed to MPP<sup>+</sup>, which was inhibited by propofol in a dose-dependent manner. Four images represent the various doses of propofol. (B) Protein carbonyl was measured by ELISA. Quantitation demonstrated increased protein carbonyl accumulation in cells exposed to MPP<sup>+</sup>, which was inhibited by propofol in a dose-dependent manner. (C) Representative fluorescence images of intracellular 4-HNE and quantitative analysis demonstrated increased intracellular 4-HNE accumulation in cells exposed to MPP<sup>+</sup>, which was inhibited by propofol in a dose-dependent manner. Analysis of variance: \*P<0.001 vs. control; #P<0.001 vs. cells exposed to MPP<sup>+</sup>. ROS, reactive oxygen species; 4-HNE, 4-hydroxy-2-nonenal; MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium. Error bars represent the standard deviation.




Figure 2. Protective effects of propofol on NO production in SH-SY5Y cells. NO was measured by 4,5-diaminofluorescein-diacetate assay. Analysis of variance: \*P<0.001 vs. control; #P<0.001 vs. cells exposed to MPP<sup>+</sup>. NO, nitric oxide; MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium. Error bars represent the standard deviation.




Figure 3. Effects of propofol on cell viability and LDH release in SH-SY5Y cells following incubation with MPP<sup>+</sup>. (A) Cell viability was determined by the MTT assay; (B) LDH release was determined using a commercial kit. Analysis of variance: \*P<0.001 vs. control; #P<0.001 vs. the cells exposed to MPP<sup>+</sup>. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium; LDH, lactate dehydrogenase. Error bars represent the standard deviation.




Figure 4. Effect of propofol on mitochondrial function in MPP<sup>+</sup>-treated SH-SY5Y cells. (A) Cell viability was determined by the fluorescence dye tetramethylrhodamine methyl ester (B) ATP levels were determined using a commercial kit. Analysis of variance: \* $P < 0.001$  vs. control; # $P < 0.001$  vs. cells exposed to MPP<sup>+</sup>. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium. Error bars represent the standard deviation.




Figure 5. Effects of propofol on the expression of Bax and Bcl-2 in SH-SY5Y cells exposed to MPP<sup>+</sup>. (A) Representative images of immunoblots for Bax and Bcl-2.  $\beta$ -actin served as a loading control. (B) Quantitative analysis of the ratio of Bax and Bcl-2. All experiments were repeated three times. Analysis of variance: \* $P < 0.001$  vs. control; # $P < 0.001$  vs. cells exposed to MPP<sup>+</sup>. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium; BCL-2, B-cell lymphoma 2; Bax, BCL2-associated X protein. Error bars represent the standard deviation.




Figure 6. Immunoblots for cytochrome *c* in cytosolic fractions demonstrating that propofol reduces the release of cytochrome *c*. COX-4 served as a control for the fraction efficiency. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium; COX-4, cytochrome *c* oxidase subunit IV isoform 1.




Figure 7. Immunoblots of cleaved caspase-3 expression demonstrating the effects of propofol on the expression level of cleaved caspase-3 in SH-SY5Y cells exposed to MPP<sup>+</sup>.  $\beta$ -actin served as a loading control. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium.

of 25 or 50  $\mu$ M propofol for 24 h. The MMP was then determined using a tetramethylrhodamine methyl ester (TMRM) fluorescence dye (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Briefly, the cells were treated with 20 nmol/l TMRM and incubated for 60 min at room temperature. Following three washes in PBS, fluorescence signals were captured using a IX71SIF-2 fluorescence microscope.

**Determination of ATP levels using a bioluminescence assay.** The cells were treated with 50  $\mu$ M MPP<sup>+</sup> in the presence or absence of 25 or 50  $\mu$ M propofol for 24 h. The levels of ATP were determined using an ATP bioluminescence assay kit (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's instructions. Briefly, the cells were lysed and centrifuged at 10,000  $\times$  g for 10 min at 4°C. The supernatants



were then collected and mixed with equal amount of luciferase reagent (Promega Corporation, Madison, WI, USA), which catalyzed light production from ATP and luciferin. The signals were recorded using a microplate luminometer (GloMax 96 Microplate Luminometer; Promega Corporation) and used to index ATP concentration.

## Results

*Propofol attenuates MPP<sup>+</sup>-induced oxidative stress.* The production of intracellular ROS in SH-SY5Y cells was assessed using the fluorescence probe, DCFH-DA. The results in the present study indicate that the intracellular ROS level in cells exposed to MPP<sup>+</sup> is significantly higher when compared with the controls, which was reduced by propofol treatment in a dose-dependent manner (Fig. 1A). Consistent with these results, the basal level of protein carbonyl (Fig. 1B) and 4-HNE (Fig. 1C) was increased by exposure to MPP<sup>+</sup>, and these increases were prevented by pretreatment with propofol.

*Propofol ameliorates the generation of NO induced by MPP<sup>+</sup>.* Intracellular production of NO is the main component of reactive nitrogen species (RNS). The intracellular NO level in SH-SY5Y cells exposed to MPP<sup>+</sup> cells was observed to be significantly higher than in control cells; however, increases in the NO level were suppressed in a dose-dependent manner by pretreatment with propofol (Fig. 2).

*Propofol inhibits MPP<sup>+</sup>-induced cell death.* The MTT reduction assay was used to determine cell viability. As presented in Fig. 3A, propofol treatment ameliorated the impaired cell viability induced by 50  $\mu$ M MPP<sup>+</sup> exposure. To further demonstrate that propofol increased cell resistance to MPP<sup>+</sup>, the levels of cellular toxicity were determined using a LDH assay. Pretreatment with propofol in SH-SY5Y cells mitigated MPP<sup>+</sup>-induced LDH release following a 24-h incubation (Fig. 3B).

*Propofol rescues MPP<sup>+</sup>-induced mitochondrial dysfunction.* The levels of MMP were investigated to determine mitochondrial function. Significantly reduced MMP in SH-SY5Y cells was observed following MPP<sup>+</sup> exposure, which was partially restored by pretreatment with propofol (Fig. 4A). Decreased levels of ATP demonstrate mitochondrial dysfunction and results from the present study indicate that the level of ATP was significantly reduced in SH-SY5Y cells exposed to MPP<sup>+</sup> when compared with the non-treated controls. However, the decreased production of ATP was partially ameliorated by propofol treatment (Fig. 4B).

*Propofol reverses the alteration of Bax and Bcl-2 induced by MPP<sup>+</sup>.* The difference between the effect of propofol on the pro- and anti-apoptotic pathways in SH-SY5Y cells was examined. The Bcl-2 family members are essential in the mitochondrial pathway of apoptosis (14). It has been previously reported that Bax is significantly upregulated and Bcl-2 is downregulated in MPP<sup>+</sup>-induced neurotoxicity (15). Results from the current study indicate that SH-SY5Y cells exhibit an increase in the expression levels of Bax and a marked decrease in the expression levels of Bcl-2 following MPP<sup>+</sup> exposure.

Furthermore, these expression levels were restored by administration of propofol (Fig. 5).

*Propofol suppresses the release of cytochrome c and caspase-3 cleavage.* Impaired MMP results in the release of cytochrome c into the cytoplasm, followed by activation of caspase-3. Therefore, the effects of propofol on cytochrome c release were investigated. As presented in Fig. 6, cytochrome c levels in the cytosol were significantly increased in cells following MPP<sup>+</sup> exposure, which was markedly prevented by propofol treatment. COX4 served as the internal control for cytosolic fractions. Notably, it was observed that caspase-3 expression levels were increased in SH-SY5Y cells following MPP<sup>+</sup> exposure; however, the increased expression was significantly attenuated by treatment with propofol (Fig. 7).

## Discussion

PD has the second highest incidence of the progressive degenerative central nervous system disorders. PD is characterized by the loss of dopaminergic neurons and muscular rigidity (16). The causes and underlying mechanisms of PD are complex and remain to be elucidated, however, free radicals produced during oxidative stress contribute to the mechanism of cell death in PD. Antioxidant and anti-apoptosis therapeutic strategies have become attractive adjunct methods for PD treatment (17). MPP<sup>+</sup> has been widely demonstrated to result in hydroxyl radical generation (4), mitochondrial dysfunction (18), and apoptosis (19) in *in vitro* PD studies. In the present study, the effects of propofol on the neurotoxicity of PD-associated MPP<sup>+</sup> were investigated. Patterns of oxidative stress, mitochondrial dysfunction and cell susceptibility were analyzed. Data from the present study demonstrates that MPP<sup>+</sup>-induced oxidative stress, mitochondrial dysfunction and apoptosis may be rescued by treatment with propofol.

Propofol is widely adopted for clinical studies as an intravenous general anesthetic (20). It is administered in anesthesia and sedation, as it is fast acting and patients rapidly regain full consciousness, as the agent does not accumulate over time with continuous infusion (21). Notably, increasing evidence has demonstrated the anti-inflammatory properties of propofol (8). Corcoran *et al* (22) reported that propofol may reduce neutrophil adhesion to vascular endothelial cells by inhibiting the expression of adhesion molecule, P-selectin. A previous study demonstrated that propofol may inhibit oxidative damage by scavenging oxygen free radicals, which is consistent with the findings of the present study that propofol may possess an anti-oxidative stress property against MPP<sup>+</sup>.

Notably, as an important neurotoxin, MPP<sup>+</sup> induces apoptotic activity in dopaminergic neurons. In the present study, apoptosis induced by MPP<sup>+</sup> is partially restored by propofol treatment. Propofol was also demonstrated to decrease the expression of Bax and increase the expression of Bcl-2 in SH-SY5Y cells exposed to MPP<sup>+</sup>. This may explain the results in the present study that propofol treatment also inhibited cytochrome c release and caspase-3 activation. The results indicate that propofol protected the SH-SY5Y cells against MPP<sup>+</sup>-induced apoptosis via the inhibition of the mitochondrial apoptosis pathway. In addition, propofol has

been demonstrated to inhibit cardiomyocyte apoptosis and the release of inflammatory factors (10).

Previous studies have reported the neuroprotective effects of propofol in neurological disorders. For example, a previous study demonstrated that propofol treatment may inhibit AD pathogenesis. The apoptosis rate was significantly decreased when cells were administered with A $\beta$ <sub>25-35</sub> and propofol, and an increase in Bcl-2 expression and a decrease in tau phosphorylation were also observed, when compared with A $\beta$ <sub>25-35</sub> treatment alone (23). In addition, previous studies have suggested that propofol may exert neuroprotective effects, particularly in ischemia-reperfusion injury conditions, including hypoxemia and hypothermia (11). In conclusion, the results of the present study demonstrate that propofol is a potential therapeutic agent for the treatment of PD. Further investigation may elucidate the underlying mechanisms of PD, as well as those of additional neurodegenerative diseases.

## References

1. Dauer W and Przedborski S: Parkinson's disease: Mechanisms and models. *Neuron* 39: 889-909, 2003.
2. Chiba K, Trevor AJ and Castagnoli N Jr: Active uptake of MPP<sup>+</sup>, a metabolite of MPTP, by brain synaptosomes. *Biochem Biophys Res Commun* 128: 1228-1232, 1985.
3. Kopin IJ and Markey SP: MPTP toxicity: Implications for research in Parkinson's disease. *Annu Rev Neurosci* 11: 81-96, 1988.
4. Obata T: Nitric oxide and MPP<sup>+</sup>-induced hydroxyl radical generation. *J Neural Transm* 113: 1131-1144, 2006.
5. Dawson TM and Dawson VL: Molecular pathways of neurodegeneration in Parkinson's disease. *Science* 302: 819-822, 2003.
6. Saraghi M, Badner VM, Golden LR and Hersch EV: Propofol: An overview of its risks and benefits. *Compend Contin Educ Dent* 34: 252-258, 2013.
7. Yamaguchi S, Hamaguchi S, Mishio M, Okuda Y and Kitajima T: Propofol prevents lipid peroxidation following transient forebrain ischemia in gerbils. *Can J Anaesth* 47: 1025-1030, 2000.
8. Inada T, Kubo K and Shingu K: Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol. *J Anesth* 25: 569-575, 2011.
9. Aarts L, van der Hee R, Dekker I, de Jong J, Langemeijer H and Bast A: The widely used anesthetic agent propofol can replace alpha-tocopherol as an antioxidant. *FEBS Lett* 357: 83-85, 1995.
10. Li H, Tan J, Zou Z, Huang CG and Shi XY: Propofol post-conditioning protects against cardiomyocyte apoptosis in hypoxia/reoxygenation injury by suppressing nuclear factor-kappa B translocation via extracellular signal-regulated kinase mitogen-activated protein kinase pathway. *Eur J Anaesthesiol* 28: 525-534, 2011.
11. Harman F, Hasturk AE, Yaman M, Arca T, Kilinc K, Sargon MF and Kaptanoglu E: Neuroprotective effects of propofol, thiopental, etomidate, and midazolam in fetal rat brain in ischemia-reperfusion model. *Childs Nerv Syst* 28: 1055-1062, 2012.
12. Sheng B, Gong K, Niu Y, Liu L, Yan Y, Lu G, Zhang L, Hu M, Zhao N, Zhang X, *et al*: Inhibition of  $\gamma$ -secretase activity reduces A $\beta$  production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: implications for the treatment of Alzheimer's disease. *Free Radic Biol Med* 46: 1362-1375, 2009.
13. Sheng BY, Niu Y, Zhou H, Yan JX, Zhao NM, Zhang XF and Gong YD: The mitochondrial function was impaired in APP knockout mouse embryo fibroblast cells. *Chin Sci Bull* 54: 1725-1731, 2009.
14. Park JR and Hockenbery DM: BCL-2, a novel regulator of apoptosis. *J Cell Biochem* 60: 12-17, 1996.
15. Zhou J, Sun Y, Zhao X, Deng Z and Pu X: 3-O-demethylswertipunicoside inhibits MPP<sup>+</sup>-induced oxidative stress and apoptosis in PC12 cells. *Brain Res* 1508: 53-62, 2013.
16. Crosiers D, Theuns J, Cras P and Van Broeckhoven C: Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. *J Chem Neuroanat* 42: 131-141, 2011.
17. Moore DJ, West AB, Dawson VL and Dawson TM: Molecular pathophysiology of Parkinson's disease. *Annu Rev Neurosci* 28: 57-87, 2005.
18. Boada J, Cutillas B, Roig T, Bermúdez J and Ambrosio S: MPP<sup>+</sup>-induced mitochondrial dysfunction is potentiated by dopamine. *Biochem Biophys Res Commun* 268: 916-920, 2000.
19. Sheehan JP, Palmer PE, Helm GA and Tuttle JB: MPP<sup>+</sup> induced apoptotic cell death in SH-SY5Y neuroblastoma cells: An electron microscope study. *J Neurosci Res* 48: 226-237, 1997.
20. Kanto JH: Propofol, the newest induction agent of anesthesia. *Int J Clin Pharmacol Ther Toxicol* 26: 41-57, 1988.
21. McNeir DA, Mainous EG and Trieger N: Propofol as an intravenous agent in general anesthesia and conscious sedation. *Anesth Prog* 35: 147-151, 1988.
22. Corcoran TB, O'Shea A, Engel A and Shorten GD: The influence of propofol on P-selectin expression and nitric oxide production in re-oxygenated human umbilical vein endothelial cells. *Acta Anaesthesiol Scand* 50: 348-354, 2006.
23. Zhang R, Xu J, Liu YY, Zuo PP, Yang N, Ji C, Wang Y, Wang H, Wu AS and Yue Y: Propofol may protect PC12 cells from  $\beta$ -amyloid<sub>25-35</sub> induced apoptosis through the GSK-3 $\beta$  signaling pathway. *Chin Med J (Engl)* 126: 1884-1889, 2013.